Navigation Links
China Yongxin Pharmaceuticals Plans to Open Eighteen New Stores in 2010 to Further Expand Customer Base and Increase Market Share
Date:1/25/2010

CHANGCHUN, China and LOS ANGELES, Jan. 25 /PRNewswire-Asia/ -- China Yongxin Pharmaceuticals, Inc. (OTC Bulletin Board: CYXN; "China Yongxin Pharmaceuticals" or the "Company"), is a leading manufacturer, distributor and retailer of Chinese traditional medicines, pharmaceutical products, natural health products, health food, cosmetics, and medical equipment in Northeastern China. The Company today announced that it plans to open twenty eight new stores in 2010.

In pursuit of the Company's new sales strategy, China Yongxin Pharmaceuticals plans to open twenty eight new retail stores in 2010 to expand its customer base and increase market share. Among them, ten stores will be located in Tianjin City with an average operating area of 160 square meters per store and a local customer population of 20,000. The Company plans to open stores at the rate of two per month from March through November 2010. These stores, considered together, are projected to achieve an average annualized revenue of $466,181.

Eight new stores will be opened in Changchun City, from March to September 2010, each with an operating area of 142.5 square meters. These new stores offer products and services to a local customer population of 15,000 each, and these stores, considered together, are expected to achieve an average annualized revenue of $371,720.

Ten new stores will be opened in Baishan City with an average operating area of 80 square meters per store. Reaching out to an average customer population of 5,000, these stores, considered together, are expected to bring an average annualized revenue stream of $193,586 to the Company.

If successfully opened, the 28 new stores together with the Company's existing stores will make Yongxin one of the top 3 drug retailers in the Jilin Province pharmaceutical retail market in terms of store presence. Already ranked as the No. 1 pharmaceutical distributor in the Jilin Province by capacity, the Company's market share is expected to substantially increase in the Northeast China area.

Already benefiting from an expanded product portfolio including 98% of the items listed on the recently issued Essential Drug List (EDL) in China and its increased marketing campaign activities, Yongxin believes these new stores will continue to contribute to revenue in the Company's retail drug operations in 2010 and beyond. In the year 2009, retail drug revenue increased by approximately 30% over the year 2008, along with an increase in gross profit of 28%.

If the Company manages to boost market share in the Jilin Province, Mr. Yongxin Liu, Chairman and Chief Executive Officer of China Yongxin, commented, "government support for our company will be further enhanced, especially following the implementation of China's $126 billion health care reform plan that focuses on providing a broader spectrum of healthcare services and pharmaceutical products to all Chinese residents. We are confident that our modernized logistics center and distribution channels, the significantly broader customer base of our chain drugstores, our extensive product portfolio, and committed management team, bode well for the long term growth of our company."

About China Yongxin Pharmaceuticals, Inc.

China Yongxin Pharmaceuticals, Inc. was founded in 1993 as the Changchun Yongxin Dirui Medical Co., Ltd. (Yongxin), is a manufacturer, retailer and distributor of Chinese traditional medicines, pharmaceutical preparations, natural health products, health food, cosmetics, and medical equipment in Northeastern China. Its retail operations began in 2004, and in 2005, it gained franchise rights from one of the world's largest drug chains for China's Jilin Province. By the end of 2007, the Company had become one of the fastest growing drug retailers in China through its retail chain of 93 drug outlets as well as wholesale distribution and manufacturing operations in Northeastern China. For more information about China Yongxin Pharmaceuticals, please visit http://www.yongxinchina.com .

Forward Looking Statements

This news release contains certain "forward-looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe," enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," "project", "expect" and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's periodic reports filed with the SEC. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved. China Yongxin Pharmaceutical Inc. does not assume any duty to publicly update or revise the material contained herein.

    For more information, please contact:

    For the Company:

     Mr. Sam Liu, COO
     China Yongxin Pharmaceuticals, Inc.
     Tel:   +1-626-581-9098
     Email: info@yongxinchina.com

    Investors:

     Mr. Matthew Hayden, HC International
     Tel:   +1-561-245-5155
     Email: matt.hayden@hcinternational.net
     Web:   http://www.hcinternational.net

SOURCE China Yongxin Pharmaceuticals, Inc.

RELATED LINKS
http://www.yongxinchina.com

'/>"/>

SOURCE China Yongxin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 2017 , ... ComplianceOnline’s Medical Device Summit is back for its 4th year. ... San Francisco, CA. The Summit brings together current and former FDA office bearers, regulators, ... government officials from around the world to address key issues in device compliance, quality ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , ... of Cancer Research, London (ICR) and ... with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple ... as MUK nine . The University of ... is partly funded by Myeloma UK, and ICR will perform ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... FirstHand program has won a US2020 STEM Mentoring Award. Representatives of the FirstHand ... Excellence in Volunteer Experience from US2020. , US2020’s mission is to change the ...
Breaking Biology Technology:
(Date:4/4/2017)... April 4, 2017   EyeLock LLC , a ... the United States Patent and Trademark Office (USPTO) has ... the linking of an iris image with a face ... represents the company,s 45 th issued patent. ... very timely given the multi-modal biometric capabilities that have ...
(Date:3/30/2017)... March 30, 2017 The research team of ... three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae ... realm of speed and accuracy for use in identification, crime investigation, ... cost. ... A research ...
(Date:3/28/2017)... The report "Video Surveillance Market ... Storage Devices), Software (Video Analytics, VMS), and Service (VSaaS, ... to 2022", published by MarketsandMarkets, the market was valued ... to reach USD 75.64 Billion by 2022, at a ... year considered for the study is 2016 and the ...
Breaking Biology News(10 mins):